Cynata Receives Ethics Committee Approval for Proposed aGvHD Phase 2 Clinical Trial
Posted: 12 April 2023 Cynata Therapeutics Limited, a clinical-stage biotechnology company specialising in cell therapeutics, has today announced that it has received approval from the Australian Human Research Ethics Committee (HREC) to commence the proposed Phase 2 clinical…
COVID VACCINE INDUCES ROBUST T CELL RESPONSES IN BLOOD CANCER PATIENTS
Posted: 12 April 2023 Researchers found that, despite being heavily immunocompromised, haematology patients generate strong cellular immune responses against SARS-CoV-2 after vaccination, on par with that of healthy individuals. Published today in Cell Reports Medicine, the research team, led…
Dose Escalation Approved in ACCENT Clinical Trial of AMP945
Posted: 12 April 2023 Amplia Therapeutics Limited is pleased to advise that following a review of safety data collected to date, the ACCENT clinical trial’s Safety Review Committee has approved dose escalation of AMP945 and recruitment of a…
Iron link offers new treatment hope for incurable blood cancer
Posted: 12 April 2023 A landmark discovery linking iron regulation to a rare blood cancer has led to clinical trials of a potential new treatment for patients with the incurable disease. The study focused on polycythemia vera (PV),…
Resistance-fighting antimalarial drug candidate enters the clinic
Posted: 12 April 2023 A new antimalarial drug candidate, discovered through a longstanding collaboration between WEHI and global biopharmaceutical company MSD has entered Phase 1 clinical testing in healthy participants. The candidate inhibits two essential enzymes required for…
Minister for Industry and Innovation launches new connected health innovation and commercialisation centre in Victoria
Posted: 12 April 2023 The Victorian Connected Health Innovation and Commercialisation Centre (CHICC), powered by ANDHealth, was formally opened today by the Minister for Industry and Innovation, The Hon Ben Carroll MP. The Victorian Government has invested $2.4…
Alterity Therapeutics Enrols First Patient in the United Kingdom in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy
Posted: 12 April 2023 Alterity Therapeutics, a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the first participant has been dosed in the United Kingdom in the Company’s Phase 2 clinical trial of…
Noxopharm to Prioritise Cutting-Edge ChromaTM & SofraTM Programs
Posted: 6 April 2023 Innovative biotech company Noxopharm Limited (ASX:NOX) announces that as part of the Board and management team’s continual operational risk and cost profile evaluation, the company has reviewed the opportunities for its growing portfolio of…
4DMedical signs first US hospital SaaS contract
Posted: 6 April 2023 Respiratory imaging technology company 4DMedical Limited today announces a significant milestone in its commercialisation journey with the signing of a five-year contract with the University of Miami to provide XV LVAS® (X-ray Velocimetry Lung…
Brain cancer trial platform to transform research and treatment
Posted: 4 April 2023 A world-first clinical trial platform is set to transform research into new therapies for brain cancer, delivering more targeted, personalised treatment for patients. The Brain-POP (brain perioperative) clinical trial platform enables doctors to precisely…
Nasodine COVID-19 Trial Concludes Recruitment – Results in June 2023
Posted: 4 April 2023 Firebrick Pharma is pleased to announce that its Phase 2 COVID-19 trial of Nasodine Nasal Spray has closed for recruitment. Nasal swabs collected from all subjects have been forwarded to a specialist virology laboratory…
Avecho Biotechnology Conducts Entiltlement Offer to Raise $11M to Fund Pivotal Phase III Clinical Trial
Posted: 4 April 2023 Avecho Biotechnology Limited has today announced that it is undertaking a capital raise seeking approximately $11 million. Proceeds from the raise will be used to fund a pivotal Phase 3 clinical trial designed to test…
